Product news

Go to navigation
Go to content

The following shows headlines of all product-related news articles published within 12-months, starting from most recent.

Pages
1
2
3
Next

- Mar 11, 2010
- AstraZeneca comments on FDA Joint Advisory Committee meeting on post-marketing safety studies for the use of LABAs in asthma
- Mar 9, 2010
- Bristol-Myers Squibb and AstraZeneca announce the commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)
- Feb 8, 2010
- US FDA approves new indication for CRESTOR® (rosuvastatin calcium)
- Dec 15, 2009
- Favorable vote from FDA Advisory Committee on benefit/risk of CRESTOR® (rosuvastatin calcium) in JUPITER study
- Dec 11, 2009
- Advisory Committee briefing materials for CRESTOR® sNDA available on US FDA web site
- Dec 10, 2009
- Phase III CONFIRM study shows FASLODEX® (fulvestrant) Injection 500 mg may delay time of disease progression over 250-mg dose in postmenopausal women with hormone receptor-positive advanced breast cancer
- Dec 4, 2009
- US FDA approves SEROQUEL XR® for add-on treatment of Major Depressive Disorder
- Dec 4, 2009
- US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
- Nov 17, 2009
- CRESTOR® reduced risk of cardiovascular events in women by nearly half in new analysis of JUPITER study
- Nov 9, 2009
- New post-hoc, pooled analysis shows SYMBICORT® improved airflow obstruction in patients with COPD

Pages
1
2
3
Next

Page tools

Stay connected with us

Stay connected with us on our social media sites